Navigation Links
Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV
Date:7/15/2009

e Commission filings, including Part II, Item 1A. "Risk Factors" in the Company's first quarter 2009 10-Q, filed May 1, 2009.

Endnotes

1 Hoffmann C (2007) The epidemiology of HIV coreceptor tropism. Eur J Med Res (2007) 12: 385-390.

2 Atazanavir sulfate is a Bristol-Myers Squibb Company prescription medicine. Please see the atazanavir product insert for information on this product.

3 Truvada is a registered trademark of Gilead Sciences, Inc. Please see the Truvada product insert for information on this product.

4 Hammer SM, Schechter M, Montaner JS, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006; 296: 827-43.

5 Data collection on adverse events of anti-HIV drugs (DAD) study group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.

6 The DAD study group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-35.

7 The DAD study group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the DAD study: a multi-cohort collaboration. www.thelancet.com published online April 2, 2008, DOI:10.1016/S0140-6736(08)60423-7.

8 Dunkle LM, Greaves WL, et al. Long-Term Safety of Vicriviroc. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Diseases Society of America (IDSA) 46th Annual Meeting; Oct. 25-28, 2008; Washington, D.C., USA; No. H-1269.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting
2. Schering-Plough Announces Results of the Early ACS Trial
3. Schering-Ploughs Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
4. Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
5. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
6. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
7. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
8. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
9. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
10. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
11. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)...  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that the number ... lead compound, LB‑100, is being conducted, has been expanded from ... , M.D., the founder and President of Lixte, said that, ... single site. Accrual of patients, however, was slower than projected. ...
(Date:1/23/2015)... Jan. 23, 2015   Leatt Corporation  (OTCQB: LEAT), a ... for all forms of sports, including extreme motor sports, ... announced today that the UISP Lega Motociclismo Lombardia, an ... riders to wear a neck brace during its racing ...
(Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... Directors has approved a share repurchase program. The open-ended ... million of Mallinckrodt plc ordinary shares. ... remain top priorities as we continue to pursue a ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... Calif., Dec. 17 PEAK Surgical, Inc., a ... dissection system based on a,proprietary technology, announced today ... granted the company 510(k) clearance to market its,PEAK(R) ... tissue during,plastic and reconstructive, ENT (ear, nose and ...
... Calif., Dec. 17 Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: ... independent,Data Safety Monitoring Board (DSMB) has determined that ... of acute ischemic stroke are unlikely,to show benefit. ... enrollment in,the trials. NTI will obtain and analyze ...
Cached Medicine Technology:PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in Expanded Indications 2PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in Expanded Indications 3PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in Expanded Indications 4Neurobiological Technologies Announces Viprinex(TM) Does Not Pass Interim Futility Analysis 2
(Date:1/22/2015)... (PRWEB) January 22, 2015 Blue Cross and ... Minnesotans who exemplify what it means to “Live Fearless.” ... for people to share their stories about how they or ... simply inspired others by living in the moment. By telling ...
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 The ... ) in the U.S. District Court, Southern District of West ... Bard, Inc. in that proceeding’s first bellwether trial. In an ... for a new trial after finding that C.R. Bard had ...
(Date:1/22/2015)... 22, 2015 A new white paper ... and person-centeredness in the long-term care environment as well ... the continuum. The paper, “The Power of Person-Centeredness in ... and practices of the patient, resident and family experience ...
(Date:1/22/2015)... has released a new blog post explaining the main features ... , Auto insurance quotes help many drivers find the best ... call an agent or visit an agency for price information. ... http://autocarinsurancebest.com/ . , Every business who relies heavily on ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post presenting the basic ... , Purchasing an accidental death and dismemberment rider for a ... rider provides benefits if the insured dies in an accident. ... of life insurance. , AD&D is not expensive and ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2
... Is Not Safe for Everyone , Not all ... epirubicin. New models can help physicians calculate the epirubicin ... for individual patients. , Oncologists frequently use anthracyclines, including ... the drugs cause lasting heart problems in a substantial ...
... percent sequentially - Q2 GAAP net profit of ... - Case shipments of 54,870 increase 6.0 percent sequentially ... CLARA, Calif., July 29 Align,Technology, Inc. (Nasdaq: ALGN ) ... June 30, 2008., Total net revenues for the second quarter ...
... ceramic implantable components surpasses projected ... ... Medical Werks, a manufacturer of,high-quality ceramic solutions for the medical device ... millionth ceramic,implantable component based on unit shipments to the orthopaedic,brachytherapy and ...
... Benjamin, MD, FACP, FACEP (E), Executive,Director, American Public ... American Public,Health Association strongly urges U.S. House members ... give the Food and Drug Administration (FDA),the authority ... is responsible for more than 400,000 deaths each,year ...
... matted protein, researchers say , , TUESDAY, July 29 (HealthDay News) ... "tangles" in the brain cells of people with Alzheimer,s disease ... are necessary to confirm whether the medication is as effective ... to be given as part of a cocktail of treatments. ...
... New Jersey Health Care Quality Institute Announces Results of Milken ... Institute Study Future Costs Can ... ... a groundbreaking study,released by the Milken Institute, the annual economic impact on New,Jersey,s economy of ...
Cached Medicine News:Health News:Also in the July 29 JNCI 2Health News:Also in the July 29 JNCI 3Health News:Also in the July 29 JNCI 4Health News:Also in the July 29 JNCI 5Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 2Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 3Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 4Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 5Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 6Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 7Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 8Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 9Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 10Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 11Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 12Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 13Health News:C5 Medical Werks Reaches Million Mark in Components Shipped 2Health News:'De-Tangling' Alzheimer's Drug Shows Promise 2Health News:'De-Tangling' Alzheimer's Drug Shows Promise 3Health News:'De-Tangling' Alzheimer's Drug Shows Promise 4Health News:Annual Economic Impact of Chronic Disease on New Jersey Economy Is $39 Billion 2Health News:Annual Economic Impact of Chronic Disease on New Jersey Economy Is $39 Billion 3Health News:Annual Economic Impact of Chronic Disease on New Jersey Economy Is $39 Billion 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... advanced nutritional formulation that provides powerful ... health. MacularProtect Complete-S, based on the ... research, delivers a diverse array of ... FloraGLO® lutein and other important nutrients. ...
Medicine Products: